Takeda Pharmaceutical Company Limited
TAK · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1,112,796 | $1,106,685 | $1,053,400 | $1,144,124 |
| % Growth | 0.6% | 5.1% | -7.9% | – |
| Cost of Goods Sold | $380,061 | $384,675 | $382,100 | $416,874 |
| Gross Profit | $732,735 | $722,010 | $671,300 | $727,250 |
| % Margin | 65.8% | 65.2% | 63.7% | 63.6% |
| R&D Expenses | $161,482 | $143,891 | $216,000 | $170,193 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $253,551 | $255,885 | $295,900 | $270,588 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $248,707 | $137,668 | $234,300 | $219,527 |
| Operating Expenses | $663,740 | $537,444 | $746,200 | $660,308 |
| Operating Income | $68,995 | $184,566 | -$74,900 | $66,942 |
| % Margin | 6.2% | 16.7% | -7.1% | 5.9% |
| Other Income/Exp. Net | -$40,821 | -$33,936 | -$32,400 | -$40,535 |
| Pre-Tax Income | $28,174 | $150,630 | -$107,300 | $26,407 |
| Tax Expense | $39,903 | $26,351 | -$4,200 | $2,572 |
| Net Income | -$11,802 | $124,243 | -$103,200 | $23,789 |
| % Margin | -1.1% | 11.2% | -9.8% | 2.1% |
| EPS | -3.74 | 39.7 | -32.62 | 7.51 |
| % Growth | -109.4% | 221.7% | -534.4% | – |
| EPS Diluted | -3.74 | 39.12 | -32.62 | 7.51 |
| Weighted Avg Shares Out | 3,155 | 3,129 | 3,163 | 3,170 |
| Weighted Avg Shares Out Dil | 3,155 | 3,176 | 3,163 | 3,170 |
| Supplemental Information | – | – | – | – |
| Interest Income | $44,396 | $73,758 | $123 | $0 |
| Interest Expense | $83,138 | $107,158 | $330 | $207 |
| Depreciation & Amortization | $205,155 | $181,636 | $189,769 | $186,955 |
| EBITDA | $316,467 | $439,424 | $181,269 | $193,007 |
| % Margin | 28.4% | 39.7% | 17.2% | 16.9% |